The peds data was a negative for exactly the reasons we said going into it - enough efficacy to continue the program, but not enough that you have to devise a novel tool to try and tease out the efficacy signal (i.e. nothing concrete like shortened hospital stay). Then the patent was a negative. so if you start at 10 and you tack on two negatives, I guess you end up at 4.9. I think the current share price is totally insane, but you have smart posters like rocky and jbog that think enta is in dire straits (and that perhaps I am insane), so here we are
have a nice weekend
Market Data 
Markets 
AI
